🔗 Share this article World Health Organization Raises Alert Over Critical Scarcity of Weight-Loss Jabs Less than a tenth of patients who could benefit from weight-loss injections including Wegovy are able to get them, warns the global health agency as it publishes its inaugural recommendations on the medications. Given more than one billion people worldwide currently classified as obese, it is urging broader and more equitable availability to these injectable treatments. Per estimates, more than two billion could be living with obesity by 2030 if no action is taken. "Our new guidelines affirms that obesity is a chronic disease that can be managed with holistic and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are key barriers to broad availability to the jabs that can help people shift considerable body mass, notes the body. GLP-1 Therapy Supply Crisis Even under the present best projected case, the production of these medications would only suffice for about 100 million people – fewer than 10% of those who need them, per the health organization. The recommendation urges governments and firms to widen access, by measures including patent sharing. A patent on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026. How Weight-Loss Injections Operate These medications imitate a natural hormone to slow digestion, reduce hunger and increase satiety so people reduce food intake. Patients usually see weight reduction within a few weeks of starting on the regular doses. Evidence suggests users may regain a significant portion after a year of discontinuing the treatment, as their usual hunger come back. Being overweight or obese raises your risk for developing health problems, like type 2 diabetes, heart disease, brain attack, and specific cancers. Obesity impacts individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
Less than a tenth of patients who could benefit from weight-loss injections including Wegovy are able to get them, warns the global health agency as it publishes its inaugural recommendations on the medications. Given more than one billion people worldwide currently classified as obese, it is urging broader and more equitable availability to these injectable treatments. Per estimates, more than two billion could be living with obesity by 2030 if no action is taken. "Our new guidelines affirms that obesity is a chronic disease that can be managed with holistic and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are key barriers to broad availability to the jabs that can help people shift considerable body mass, notes the body. GLP-1 Therapy Supply Crisis Even under the present best projected case, the production of these medications would only suffice for about 100 million people – fewer than 10% of those who need them, per the health organization. The recommendation urges governments and firms to widen access, by measures including patent sharing. A patent on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026. How Weight-Loss Injections Operate These medications imitate a natural hormone to slow digestion, reduce hunger and increase satiety so people reduce food intake. Patients usually see weight reduction within a few weeks of starting on the regular doses. Evidence suggests users may regain a significant portion after a year of discontinuing the treatment, as their usual hunger come back. Being overweight or obese raises your risk for developing health problems, like type 2 diabetes, heart disease, brain attack, and specific cancers. Obesity impacts individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.